Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec 21;6(1):435.
doi: 10.1038/s41392-021-00853-4.

Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry

Shulong Zu #  1   2   3   4 , Dan Luo #  4 , Lili Li #  2   3 , Qing Ye #  4 , Rui-Ting Li  4 , Yanan Wang  5 , Meiling Gao  2   3 , Heng Yang  6   7 , Yong-Qiang Deng  8 , Genhong Cheng  9
Affiliations
Comment

Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry

Shulong Zu et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Tamoxifen and clomiphene inhibit SARS-CoV-2 infection in vitro and in vivo. a Vero cells were pretreated with different doses of tamoxifen or clomiphene for 12 h, then the cells were infected with SARS-CoV-2 at 100 median tissue culture infectious dose (TCID50). The cell supernatants were used to test virus RNA loads by qRT-PCR at 48 h post infection (hpi). The EC50s of tamoxifen and clomiphene on Vero cells were indicated. b, c Vero cells were pretreated and infected as in (a). After 48 h, the cells were collected and treated for western blot. SARS-CoV-2 S protein and GAPDH were tested. The black arrow indicates bands corresponding to uncleaved S proteins (S0) and gray arrow indicates bands corresponding to the S2 subunit. The quantitative results of the expression of S protein of SARS-CoV-2 were labeled. d, e Vero cells were pretreated and infected as in (a). After 48 h, the cells were fixed and treated for immunofluorescence assay. SARS-CoV-2 S protein was stained in green, and DAPI in blue. Scale bars, 100 μm. f RBD of SARS-CoV-2 S protein and ACE2 protein were used in ELISA assay to test the inhibition of tamoxifen and clomiphene to the binding activity. SARS-CoV-2 antibody was used as a positive control. g Huh7 cells were pretreated with tamoxifen and clomiphene, then were infected with SARS-CoV-2 pseudovirus. After 24 h, the cells were collected to examine the luciferase activity of pseudovirus. h, i Huh7 cells were treated as in (g), then were infected with P.1.351 (h) and P.1.617 (i) pseudovirus. After 24 h, the cells were collected to examine the luciferase activity of pseudovirus. j 293T cells were transfected with GFP-tagged SARS-CoV-2 S protein-expressing plasmid and then co-cultured with Huh7 cells. After 12 h, the cells were treated with tamoxifen and clomiphene for 24 h, and fixed with 4% paraformaldehyde, the membrane fusion was observed by fluorescence microscopy, white arrows indicate syncytium formation. Scale bars, 100 μm. k, l The mice trachea and lung were collected for qRT-PCR to test the virus loads. m, n Mice lungs were fixed with 4% paraformaldehyde for RNAscope to display SARS-CoV-2 RNA in mice lung (m) and stained with H&E to show the inflammatory cell infiltration (n). Scale bars, 100 μm. Quantitative data are represented as mean ± SEM; ns, not significant, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001
See this image and copyright information in PMC

Comment on

  • Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.
    Gu H, Chen Q, Yang G, He L, Fan H, Deng YQ, Wang Y, Teng Y, Zhao Z, Cui Y, Li Y, Li XF, Li J, Zhang NN, Yang X, Chen S, Guo Y, Zhao G, Wang X, Luo DY, Wang H, Yang X, Li Y, Han G, He Y, Zhou X, Geng S, Sheng X, Jiang S, Sun S, Qin CF, Zhou Y. Gu H, et al. Science. 2020 Sep 25;369(6511):1603-1607. doi: 10.1126/science.abc4730. Epub 2020 Jul 30. Science. 2020. PMID: 32732280 Free PMC article.

References

    1. Martin WR, Cheng F. Repurposing of FDA-approved toremifene to treat COVID-19 by blocking the spike glycoprotein and NSP14 of SARS-CoV-2. J. Proteome Res. 2020;19:4670–4677. doi: 10.1021/acs.jproteome.0c00397. - DOI - PMC - PubMed
    1. Gu H, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369:1603–1607. doi: 10.1126/science.abc4730. - DOI - PMC - PubMed
    1. Zhang Y, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:181–192. doi: 10.1016/S1473-3099(20)30843-4. - DOI - PMC - PubMed
    1. Walsh EE, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906. - DOI - PMC - PubMed
    1. Voysey M, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–891. doi: 10.1016/S0140-6736(21)00432-3. - DOI - PMC - PubMed